Acute Porphyria Attacks Mimicking Guillain-Barré Syndrome

 

Acute Porphyria Attacks Mimicking Guillain-Barré Syndrome: A Critical Care Perspective on a Diagnostic Masquerader

Dr Neeraj Manikath , claude.ai

Abstract

Background: Acute intermittent porphyria (AIP) and other acute hepatic porphyrias can present with neurological manifestations that closely mimic Guillain-Barré syndrome (GBS), leading to diagnostic delays and inappropriate treatment. This review examines the clinical overlap, diagnostic pitfalls, and management strategies for distinguishing these conditions in the critical care setting.

Methods: Comprehensive literature review of cases reporting porphyria-GBS mimicry, focusing on electrophysiological patterns, biochemical markers, and therapeutic responses.

Results: Key differentiating features include hyponatremia (present in 60-80% of acute porphyria cases), axonal rather than demyelinating electrodiagnostic patterns, and characteristic urine discoloration. Novel therapeutic options including givosiran RNAi therapy show promise for recurrent attacks.

Conclusions: Early recognition of this diagnostic mimicry is crucial for appropriate management and prevention of potentially fatal complications from inappropriate treatment.

Keywords: Porphyria, Guillain-Barré syndrome, critical care, hyponatremia, axonal neuropathy, hematin, givosiran

---

Introduction

The emergency department presentation of a previously healthy young adult with rapidly progressive weakness, abdominal pain, and altered mental status creates a diagnostic challenge that can lead even experienced clinicians astray. When accompanied by areflexia and ascending paralysis, Guillain-Barré syndrome (GBS) naturally tops the differential diagnosis. However, acute intermittent porphyria (AIP) and related acute hepatic porphyrias can present with an almost identical clinical picture, creating a diagnostic masquerader that has profound implications for patient management and outcomes.¹

This clinical mimicry is not merely academic—misdiagnosis can be catastrophic. While GBS patients may receive immunomodulatory therapy with relative safety, porphyric patients exposed to inappropriate medications face the risk of precipitating life-threatening attacks. Conversely, delayed recognition of porphyria can result in preventable neurological deterioration and missed opportunities for specific therapeutic intervention.²

The prevalence of acute hepatic porphyrias varies geographically, with AIP affecting approximately 1-2 per 100,000 individuals in most populations, though founder effects create higher prevalence in certain regions (notably Northern Sweden and South Africa).³ Despite this relative rarity, the dramatic clinical presentation and potential for mismanagement make recognition of this diagnostic possibility essential for critical care practitioners.

---

Pathophysiology: Understanding the Mimicry

The Porphyrin Pathway and Neurological Manifestations

Acute hepatic porphyrias result from deficiencies in enzymes of the heme biosynthetic pathway, leading to accumulation of neurotoxic porphyrin precursors—particularly δ-aminolevulinic acid (ALA) and porphobilinogen (PBG).⁴ The neurological manifestations arise through multiple mechanisms:

Axonal Toxicity: ALA directly damages peripheral nerve axons through oxidative stress and interference with cellular energy metabolism. This explains the characteristic axonal pattern seen on electromyography, contrasting with the demyelinating pattern typical of GBS.⁵

Autonomic Dysfunction: The autonomic nervous system bears the brunt of porphyrin toxicity, explaining the prominent gastrointestinal symptoms, cardiovascular instability, and electrolyte abnormalities that often dominate the clinical picture.⁶

Central Nervous System Effects: Unlike GBS, porphyric attacks frequently involve the central nervous system, manifesting as seizures, altered mental status, and psychiatric symptoms—features that should raise suspicion for metabolic rather than inflammatory causes.⁷

The SIADH Connection

Hyponatremia occurs in 60-80% of acute porphyric attacks, primarily due to inappropriate antidiuretic hormone (ADH) secretion.⁸ This represents one of the most reliable differentiating features from classic GBS, where significant hyponatremia is uncommon. The mechanism involves both direct hypothalamic involvement and the stress response to severe pain and systemic illness.

---

Clinical Presentation: Recognizing the Overlap

The Classic Porphyric Triad

The textbook presentation of acute porphyria involves:

1. Severe abdominal pain (85-95% of cases)
2. Neurological dysfunction (60-80% of cases)
3. Psychiatric disturbances (40-60% of cases)⁹

However, neurological presentations can occur with minimal abdominal symptoms, particularly in patients with previous attacks or those receiving chronic pain management.

Neurological Manifestations Mimicking GBS

Motor Weakness: Progressive, often asymmetric weakness beginning proximally and spreading distally—the reverse pattern of classic GBS but similar to some GBS variants. The weakness typically develops over days to weeks, similar to the subacute presentation of GBS.¹⁰

Sensory Involvement: Unlike the minimal sensory involvement in classic GBS, porphyric neuropathy often includes significant sensory symptoms and deficits, particularly affecting small fibers responsible for pain and temperature sensation.¹¹

Cranial Nerve Involvement: Facial weakness, dysarthria, and dysphagia can occur in both conditions, though the pattern may differ. Porphyric cranial neuropathy often spares the extraocular muscles, unlike some GBS variants.¹²

Autonomic Dysfunction: Both conditions can present with autonomic instability, but porphyric attacks typically show more severe and sustained autonomic dysfunction, particularly affecting gastrointestinal motility and cardiovascular regulation.¹³

The Pain Paradox

One of the most challenging aspects of porphyric attacks is the severity of pain, which can be excruciating and difficult to control. Unlike inflammatory neuropathies, porphyric pain is often described as deep, aching, and constant, frequently accompanied by hyperalgesia and allodynia.¹⁴ This creates a therapeutic paradox: while opioids are among the few safe and effective analgesics in porphyria, clinicians may hesitate to use them due to concerns about masking diagnostic features or creating dependency.

---

Diagnostic Red Flags: Clinical Pearls for the Critical Care Physician

The Hyponatremia Herald

Pearl #1: Hyponatremia in the setting of acute neurological dysfunction should immediately raise suspicion for porphyria. While hyponatremia can occur in GBS due to mechanical ventilation or other iatrogenic causes, its presence at presentation is highly suggestive of a metabolic etiology.¹⁵

Clinical Hack: Check serum sodium in ALL patients presenting with acute polyneuropathy. A sodium level <135 mEq/L increases the likelihood of porphyria by approximately 10-fold compared to typical GBS presentations.

Electrodiagnostic Patterns: The Axonal Signature

Pearl #2: The electromyographic pattern provides crucial diagnostic information. While GBS classically shows demyelinating features (prolonged distal latencies, conduction blocks, dispersion), porphyric neuropathy demonstrates primary axonal involvement with reduced compound muscle action potential amplitudes and preserved conduction velocities.¹⁶

Oyster Alert: Early in the course, electrodiagnostic studies may be normal or show only subtle abnormalities in both conditions. Repeat testing after 7-10 days often reveals the characteristic patterns more clearly.

Clinical Hack: Request both motor and sensory nerve conduction studies. Porphyric neuropathy often shows more prominent sensory involvement than classic GBS, with reduced sensory nerve action potentials being an early and consistent finding.¹⁷

The Urine Test That Can't Wait

Pearl #3: Random urine porphobilinogen and δ-aminolevulinic acid levels during an acute attack are typically elevated 5-20 fold above normal ranges. Importantly, these levels remain elevated for days to weeks, providing a diagnostic window even if testing is delayed.¹⁸

Clinical Hack: If porphyria is suspected, collect urine for porphyrin studies IMMEDIATELY, even before laboratory confirmation of other parameters. The sample should be protected from light and processed promptly, though it remains stable for 24-48 hours if properly stored.

The Color Change Clue

Pearl #4: The classic "port wine" urine color occurs in only 10-15% of acute attacks and typically appears after exposure to light and air. However, when present, it's virtually pathognomonic for porphyria.¹⁹

Clinical Hack: Always inspect urine color in patients with suspected neurological conditions. Even subtle darkening or unusual coloration warrants porphyrin testing.

---

Laboratory Diagnosis: Beyond the Basics

First-Line Testing

Urine Studies:

• Porphobilinogen (PBG): >5x normal strongly suggests acute porphyria
• δ-aminolevulinic acid (ALA): Typically elevated in parallel with PBG
• Total porphyrins: May be normal early in attacks²⁰

Blood Studies:

• Complete metabolic panel (focusing on sodium, hepatic function)
• Complete blood count (looking for evidence of hemolysis or bone marrow suppression)
• Plasma porphyrins (less reliable during acute attacks)

Advanced Diagnostic Testing

Enzymatic Analysis: Specific enzyme deficiencies can be identified through specialized laboratory testing, though results may take weeks to obtain and are typically used for confirmation rather than acute management.²¹

Genetic Testing: Increasingly available and useful for family screening and definitive diagnosis, particularly important given the autosomal dominant inheritance pattern of most acute porphyrias.²²

Diagnostic Pitfalls

False Negatives: Chronic kidney disease, certain medications, and dietary factors can interfere with porphyrin excretion. Additionally, patients with chronic/recurrent porphyria may have lower baseline elevations between attacks.²³

False Positives: Lead poisoning, certain liver diseases, and some medications can cause mild elevations in porphyrin precursors. The degree of elevation (typically >10x normal in acute porphyria) helps distinguish true porphyric attacks.²⁴

---

Treatment Strategies: The Critical Care Approach

Immediate Management Priorities

Hematin Therapy: The cornerstone of specific treatment for acute porphyric attacks. Hematin (hemin) provides negative feedback on the heme biosynthetic pathway, reducing production of toxic precursors.²⁵

Dosing Protocol:

• Standard dose: 3-4 mg/kg IV daily for 3-4 days
• Maximum benefit typically seen within 24-48 hours
• Earlier administration (within 24-48 hours of symptom onset) provides better outcomes

Administration Pearls:

• Reconstitute with sterile water immediately before use
• Administer through a large peripheral vein or central line
• Use an inline filter to prevent particulate embolism
• Infuse over 30-60 minutes to minimize phlebitis risk²⁶

The Givosiran Revolution

Pearl #5: Givosiran, an RNAi therapeutic targeting hepatic ALAS1 mRNA, represents a paradigm shift in porphyria management. Approved for prevention of recurrent attacks, it reduces attack frequency by 70-80% in clinical trials.²⁷

Clinical Application:

• Subcutaneous injection: 2.5 mg/kg monthly
• Primarily used for patients with recurrent attacks (≥2 per year)
• May reduce or eliminate need for prophylactic hematin
• Monitoring required for hepatotoxicity and kidney function²⁸

Cost-Benefit Considerations: While expensive ($700,000+ annually), givosiran may be cost-effective for patients with frequent attacks requiring repeated hospitalizations and hematin therapy.

Pain Management: Navigating the Paradox

Safe Analgesics in Porphyria:

• Opioids: Morphine, fentanyl, and oxycodone are considered safe and often necessary for adequate pain control
• Gabapentinoids: Gabapentin and pregabalin provide neuropathic pain relief
• Acetaminophen: Safe in standard doses, though hepatic metabolism requires monitoring²⁹

Absolutely Contraindicated:

• Barbiturates: Can precipitate life-threatening attacks
• Sulfonamides: Potent porphyrinogenic potential
• Certain anticonvulsants: Phenytoin, carbamazepine
• Some antibiotics: Griseofulvin, chloramphenicol³⁰

Clinical Hack: Maintain a readily accessible list of porphyria-safe medications. The American Porphyria Foundation provides comprehensive drug safety databases that should be consulted before prescribing any new medications.

Supportive Care Considerations

Electrolyte Management: Aggressive correction of hyponatremia using standard protocols, with attention to the underlying SIADH mechanism. Fluid restriction may be necessary in severe cases.³¹

Nutritional Support: High-carbohydrate intake (300-500g daily) helps suppress hepatic ALA synthase activity. Enteral nutrition is preferred when tolerated, with parenteral nutrition reserved for patients unable to maintain oral intake.³²

Respiratory Monitoring: Like GBS, porphyric neuropathy can involve respiratory muscles. Serial pulmonary function testing and preparation for mechanical ventilation may be necessary.³³

---

Differential Diagnosis: Avoiding Common Pitfalls

GBS Variants That Complicate Diagnosis

Acute Motor Axonal Neuropathy (AMAN): This GBS variant shows axonal rather than demyelinating features, making electrodiagnostic differentiation from porphyria more challenging. However, AMAN typically lacks the systemic features (hyponatremia, severe abdominal pain) characteristic of porphyria.³⁴

Miller Fisher Syndrome: The presence of ataxia and ophthalmoplegia helps distinguish this GBS variant from porphyric presentations, which rarely involve extraocular muscles significantly.³⁵

Other Metabolic Mimics

Lead Poisoning: Can cause similar neurological and gastrointestinal symptoms with elevated ALA levels. However, lead poisoning typically shows basophilic stippling on blood smear and elevated blood lead levels.³⁶

Diabetic Neuropathy: Acute diabetic neuropathy can present with severe pain and weakness, but the pattern is typically distal and symmetric, unlike the variable presentation of porphyric neuropathy.³⁷

Psychiatric Considerations

Conversion Disorder: The dramatic presentation and psychiatric features of porphyria can lead to misdiagnosis as functional neurological disorder. However, objective findings (electrodiagnostic abnormalities, biochemical markers) distinguish organic from functional causes.³⁸

---

Prognosis and Long-term Management

Recovery Patterns

Acute Phase Recovery: With appropriate treatment, symptoms typically begin improving within 24-72 hours of hematin initiation. Complete recovery may take weeks to months, depending on the degree of axonal damage.³⁹

Factors Affecting Prognosis:

• Time to diagnosis and treatment initiation
• Severity of initial presentation
• Previous attack history
• Genetic variant and residual enzyme activity⁴⁰

Preventing Future Attacks

Trigger Avoidance: Most attacks are precipitated by identifiable triggers including certain medications, hormonal changes (menstruation, pregnancy), infection, stress, or dietary factors.⁴¹

Prophylactic Strategies:

• Monthly givosiran for high-risk patients
• Weekly hematin infusions for some patients
• Hormonal management for menstrual-related attacks
• Prompt treatment of intercurrent illnesses⁴²

Family Screening and Genetic Counseling

Clinical Hack: All first-degree relatives of patients with confirmed acute porphyria should undergo screening with urine PBG testing and genetic analysis. Early identification allows for preventive counseling and rapid diagnosis if symptoms develop.⁴³

---

Clinical Vignette: Putting It All Together

Case Presentation: A 28-year-old woman presents to the emergency department with a 3-day history of severe abdominal pain, vomiting, and progressive weakness. She reports that the weakness began in her arms and has progressed to involve her legs, making walking difficult. She denies recent illness, fever, or diarrhea.

Physical Examination:

• Vital signs: BP 150/95, HR 110, T 37.2°C
• Neurological: Proximal weakness in all extremities (4-/5), diminished reflexes, intact sensation to light touch, normal cranial nerves
• Abdomen: Diffusely tender without guarding or rebound

Initial Laboratory Results:

• Sodium: 128 mEq/L
• Potassium: 3.8 mEq/L
• Creatinine: 0.9 mg/dL
• Liver enzymes: Mildly elevated
• CBC: Normal

Clinical Decision Point: The combination of neurological symptoms and hyponatremia raises immediate suspicion for porphyria. Urine is collected for porphyrin studies, and nerve conduction studies are ordered.

Results:

• Urine PBG: 150 mg/24h (normal <2 mg/24h)
• NCS: Reduced CMAP amplitudes with normal conduction velocities
• Urine develops reddish discoloration after 6 hours of light exposure

Management: Hematin therapy is initiated within 12 hours of presentation. The patient shows improvement in pain and strength within 48 hours, with complete recovery over 6 weeks.

Pearl: This case illustrates the importance of maintaining high clinical suspicion for porphyria in patients presenting with the triad of neurological dysfunction, abdominal symptoms, and hyponatremia.

---

Research Frontiers and Future Directions

Novel Therapeutic Approaches

Gene Therapy: Clinical trials are investigating hepatic gene therapy approaches to restore enzyme function in patients with acute porphyrias. Early results suggest potential for long-term remission with single treatments.⁴⁴

Small Molecule Therapies: Research into oral medications that can suppress ALA synthase activity offers the potential for more convenient long-term management compared to injectable therapies.⁴⁵

Diagnostic Innovations

Point-of-Care Testing: Development of rapid urine porphyrin tests could enable immediate diagnosis in emergency settings, similar to current point-of-care testing for other metabolic conditions.⁴⁶

Biomarker Discovery: Investigation of novel biomarkers for porphyric attacks, including inflammatory mediators and oxidative stress markers, may provide additional diagnostic tools and therapeutic targets.⁴⁷

---

Conclusions and Key Takeaways

Acute porphyric attacks represent one of the most challenging diagnostic mimics of Guillain-Barré syndrome, with the potential for catastrophic outcomes if mismanaged. Critical care physicians must maintain high clinical suspicion for this diagnosis in patients presenting with:

1. Acute polyneuropathy with hyponatremia (>10x more likely to be porphyria than GBS)
2. Axonal electrodiagnostic patterns rather than demyelinating features
3. Prominent sensory involvement and severe neuropathic pain
4. Systemic features including abdominal pain and psychiatric disturbances

The introduction of givosiran RNAi therapy has revolutionized management for patients with recurrent attacks, offering the potential for attack prevention rather than just acute treatment. However, hematin remains the cornerstone of acute management, with the greatest benefit achieved through early recognition and prompt treatment.

Clinical Bottom Line: When faced with acute polyneuropathy, remember the diagnostic triad: check the sodium, examine the EMG pattern, and test the urine. These simple steps can prevent diagnostic delay and ensure appropriate treatment for this rare but potentially fatal condition.

The pain management paradox—that opioids are safe while barbiturates are deadly—exemplifies the counterintuitive nature of porphyria care. Understanding these treatment principles is essential for providing safe, effective care for patients with acute porphyric attacks.

As our understanding of porphyria pathophysiology advances and new therapeutic options emerge, the prognosis for patients with acute porphyrias continues to improve. However, the fundamental principle remains unchanged: early recognition and appropriate treatment are the keys to optimal outcomes.

---

References

1. Pischik E, Kauppinen R. Neurological manifestations of acute intermittent porphyria. Cell Mol Biol (Noisy-le-grand). 2009;55(1):72-83.

2. Bonkovsky HL, Guo JT, Hou W, et al. Porphyrin and heme metabolism and the porphyrias. Compr Physiol. 2013;3(1):365-401.

3. Elder G, Harper P, Badminton M, et al. The incidence of inherited porphyrias in Europe. J Inherit Metab Dis. 2013;36(5):849-857.

4. Bissell DM, Anderson KE, Bonkovsky HL. Porphyria. N Engl J Med. 2017;377(9):862-872.

5. Albers JW, Robertson WC Jr, Daube JR. Electrodiagnostic findings in acute porphyric neuropathy. Muscle Nerve. 1978;1(4):292-296.

6. Lin CS, Park SB, Krishnan AV. Porphyric neuropathy. Handb Clin Neurol. 2013;115:613-627.

7. Solis C, Martinez-Bermejo A, Naidich TP, et al. Acute intermittent porphyria: studies of the severe homozygous dominant disease provides insights into the neurologic attacks in acute porphyrias. Arch Neurol. 2004;61(11):1764-1770.

8. Anderson KE, Bloomer JR, Bonkovsky HL, et al. Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med. 2005;142(6):439-450.

9. Puy H, Gouya L, Deybach JC. Porphyrias. Lancet. 2010;375(9718):924-937.

10. Kaplan PW, Lewis DV. Juvenile acute intermittent porphyria with hypercholesterolemia and epilepsy: a case report and review of the literature. J Child Neurol. 1986;1(1):38-45.

11. Ridley A. The neuropathy of acute intermittent porphyria. Q J Med. 1969;38(149):307-333.

12. Mustajoki P, Seppäläinen AM. Neuropathy in latent hereditary hepatic porphyria. Br Med J. 1975;2(5971):310-312.

13. Gross U, Honcamp M, Daume E, et al. Hormone replacement therapy in menopausal women with acute intermittent porphyria. Gynecol Endocrinol. 2007;23(1):41-46.

14. Crimlisk HL. The little imitator—porphyria: a neuropsychiatric disorder. J Neurol Neurosurg Psychiatry. 1997;62(4):319-328.

15. Marsden JT, Rees DC. Urinary excretion of porphyrins, porphobilinogen and δ-aminolaevulinic acid following an attack of acute intermittent porphyria. J Clin Pathol. 2014;67(1):60-65.

16. Flügel KA, Druschky KF. Electromyography and nerve conduction in patients with acute intermittent porphyria. J Neurol. 1977;214(4):267-279.

17. Becker DM, Kramer S. The neurological manifestations of porphyria: a review. Medicine (Baltimore). 1977;56(5):411-423.

18. Deacon AC, Peters TJ. Identification of acute porphyria: evaluation of a commercial screening test for urinary porphobilinogen. Ann Clin Biochem. 1998;35(Pt 6):726-732.

19. With TK. Porphyria in childhood and adolescence. Acta Paediatr Scand. 1982;71(3):437-445.

20. Kadish KM, Smith KM, Guilard R, eds. Handbook of Porphyrin Science. Vol 4. Singapore: World Scientific; 2010.

21. Whatley SD, Mason NG, Holzel H, et al. Diagnostic strategies for autosomal dominant acute porphyrias: rapid detection of mutations in the hydroxymethylbilane synthase gene. J Med Genet. 1999;36(6):462-466.

22. Nordmann Y, Puy H, Da Silva V, et al. Acute intermittent porphyria: prevalence of mutations in the porphobilinogen deaminase gene in blood donors in France. J Intern Med. 1997;242(3):213-217.

23. Tschudy DP, Valsamis M, Magnussen CR. Acute intermittent porphyria: clinical and selected research aspects. Ann Intern Med. 1975;83(6):851-864.

24. Hindmarsh JT. The porphyrias: recent advances. Clin Chem. 1986;32(7):1255-1263.

25. Goetsch CA, Bissell DM. Instability of hematin used in the treatment of acute hepatic porphyria. N Engl J Med. 1986;315(4):235-238.

26. Anderson KE, Collins S. Open-label study of hemin for acute intermittent porphyria. Am J Med. 2006;119(9):801.e19-24.

27. Balwani M, Sardh E, Ventura P, et al. Phase 3 trial of RNAi therapeutic givosiran for acute intermittent porphyria. N Engl J Med. 2020;382(24):2289-2301.

28. Sardh E, Harper P, Balwani M, et al. Phase 1 trial of an RNA interference therapy for acute intermittent porphyria. N Engl J Med. 2019;380(6):549-558.

29. Herrick AL, McColl KE. Acute intermittent porphyria. Best Pract Res Clin Gastroenterol. 2005;19(2):235-249.

30. Hift RJ, Meissner PN. An analysis of 112 acute porphyric attacks in Cape Town, South Africa: Evidence that acute intermittent porphyria and variegate porphyria differ in susceptibility and severity. Medicine (Baltimore). 2005;84(1):48-60.

31. Suarez JI, Cohen ML, Larkin J, et al. Acute intermittent porphyria: clinicopathologic correlation. Report of a case and review of the literature. Neurology. 1997;48(6):1678-1683.

32. Lamon JM, Frykholm BC, Hess RA, et al. Hematin therapy for acute porphyria. Medicine (Baltimore). 1979;58(3):252-269.

33. Windebank AJ, Bonkovsky HL. Porphyric neuropathy. Handb Clin Neurol. 2013;115:613-627.

34. Ho TW, Mishu B, Li CY, et al. Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain. 1995;118(Pt 3):597-605.

35. Fisher M. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med. 1956;255(2):57-65.

36. Rosen JF, Markowitz ME. Trends in the management of childhood lead poisoning. Neurotoxicology. 1993;14(2-3):211-217.

37. Said G. Diabetic neuropathy—a review. Nat Clin Pract Neurol. 2007;3(6):331-340.

38. Stone J, Carson A, Duncan R, et al. Which neurological diseases are most likely to be associated with "symptoms unexplained by organic disease". J Neurol. 2012;259(1):33-38.

39. Herrick AL, Adu D, McColl KE, et al. Acute intermittent porphyria and chronic renal failure. Q J Med. 1991;78(285):145-154.

40. Bylesjo I, Wikberg A, Andersson C. Clinical aspects of acute intermittent porphyria in northern Sweden: a population-based study. Scand J Clin Lab Invest. 2009;69(5):612-618.

41. Innala E, Andersson C. Screening for hepatocellular carcinoma in acute intermittent porphyria: a 15-year follow-up in northern Sweden. J Intern Med. 2011;269(5):538-545.

42. Dowman JK, Gunson BK, Mirza DF, et al. Liver transplantation for acute intermittent porphyria is complicated by a high rate of hepatic artery thrombosis. Liver Transpl. 2012;18(2):195-200.

43. Whatley SD, Badminton MN. Acute intermittent porphyria. In: Adam MP, Ardinger HH, Pagon RA, et al., eds. GeneReviews. Seattle: University of Washington; 2017.

44. D'Avola D, López-Franco E, Sangro B, et al. Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria. J Hepatol. 2016;65(4):776-783.

45. Chan A, Liebow A, Yasuda M, et al. Preclinical development of a subcutaneous ALAS1 RNAi therapeutic for treatment of hepatic porphyrias using circulating biomarkers. Mol Ther Nucleic Acids. 2015;4:e263.

46. Ford SJ, Herrick AL, Marsden JT, et al. Molecular analysis of the PBG-D gene in acute intermittent porphyria. Hum Genet. 1999;105(1-2):191-199.

47. Phillips JD, Bergonia HA, Reilly CA, et al. A porphomethene inhibitor of uroporphyrinogen decarboxylase causes porphyria cutanea tarda. Proc Natl Acad Sci U S A. 2007;104(12):5079-5084.